img

Global Age-Related Macular Degeneration (AMD) Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Age-Related Macular Degeneration (AMD) Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Age-related macular degeneration is a bilateral ocular condition in which the central area of the retina, known as the macula, is affected.
Due to the COVID-19 pandemic, the global Age-Related Macular Degeneration (AMD) Therapeutics market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Wet AMD accounting for % of the Age-Related Macular Degeneration (AMD) Therapeutics global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
Age-related macular degeneration is a progressive condition, and it is common among the geriatric population. The growing geriatric population is contributing to the rising incidence of age-related macular degeneration globally. As a result, there is a high demand for therapeutics to treat the condition. Pharmaceutical companies are leveraging this opportunity and are focusing on releasing drugs to treat age-related macular degeneration.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Age-Related Macular Degeneration (AMD) Therapeutics market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Age-Related Macular Degeneration (AMD) Therapeutics market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Age-Related Macular Degeneration (AMD) Therapeutics market. Readers of the report can become informed about current and future trends of the global Age-Related Macular Degeneration (AMD) Therapeutics market and how they will impact market growth during the forecast period.



By Company


Amgen Inc.
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
Segment by Type
Wet AMD
Dry AMD

Segment by Application


Hospital
Clinic
Research Institute
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Age-Related Macular Degeneration (AMD) Therapeutics in global and regional level.
Chapter 3Detailed analysis of Age-Related Macular Degeneration (AMD) Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Age-Related Macular Degeneration (AMD) Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Wet AMD
1.2.3 Dry AMD
1.3 Market by Application
1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Institute
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2018-2034)
2.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2018-2024)
2.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Age-Related Macular Degeneration (AMD) Therapeutics Countries Ranking by Market Size
3 Age-Related Macular Degeneration (AMD) Therapeutics Competitive by Company
3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players
3.1.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players (2018-2024)
3.1.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Players (2018-2024)
3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Age-Related Macular Degeneration (AMD) Therapeutics Revenue
3.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Concentration Ratio
3.4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Age-Related Macular Degeneration (AMD) Therapeutics Revenue in 2022
3.5 Global Key Players of Age-Related Macular Degeneration (AMD) Therapeutics Head office and Area Served
3.6 Global Key Players of Age-Related Macular Degeneration (AMD) Therapeutics, Product and Application
3.7 Global Key Players of Age-Related Macular Degeneration (AMD) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Age-Related Macular Degeneration (AMD) Therapeutics Breakdown Data by Type
4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Historic Revenue by Type (2018-2024)
4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Revenue by Type (2024-2034)
5 Global Age-Related Macular Degeneration (AMD) Therapeutics Breakdown Data by Application
5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Size by Application (2018-2024)
5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2024)
6.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2034)
6.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2034)
6.4 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2024)
7.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2034)
7.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2034)
7.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2024)
8.2 Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2034)
8.3 Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2034)
8.4 Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2024)
9.2 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2034)
9.3 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2034)
9.4 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2024)
10.2 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2034)
10.3 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2034)
10.4 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Details
11.1.2 Amgen Inc. Business Overview
11.1.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Products and Services
11.1.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024)
11.1.5 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics SWOT Analysis
11.1.6 Amgen Inc. Recent Development
11.2 Bausch Health Companies, Inc.
11.2.1 Bausch Health Companies, Inc. Company Details
11.2.2 Bausch Health Companies, Inc. Business Overview
11.2.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Products and Services
11.2.4 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024)
11.2.5 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics SWOT Analysis
11.2.6 Bausch Health Companies, Inc. Recent Development
11.3 F. Hoffmann-La Roche Ltd.
11.3.1 F. Hoffmann-La Roche Ltd. Company Details
11.3.2 F. Hoffmann-La Roche Ltd. Business Overview
11.3.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Products and Services
11.3.4 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024)
11.3.5 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics SWOT Analysis
11.3.6 F. Hoffmann-La Roche Ltd. Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Products and Services
11.4.4 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024)
11.4.5 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics SWOT Analysis
11.4.6 Novartis AG Recent Development
11.5 Regeneron Pharmaceuticals Inc.
11.5.1 Regeneron Pharmaceuticals Inc. Company Details
11.5.2 Regeneron Pharmaceuticals Inc. Business Overview
11.5.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Products and Services
11.5.4 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024)
11.5.5 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics SWOT Analysis
11.5.6 Regeneron Pharmaceuticals Inc. Recent Development
12 Age-Related Macular Degeneration (AMD) Therapeutics Market Dynamics
12.1 Age-Related Macular Degeneration (AMD) Therapeutics Industry Trends
12.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
12.3 Age-Related Macular Degeneration (AMD) Therapeutics Market Challenges
12.4 Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Wet AMD
Table 3. Key Players of Dry AMD
Table 4. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 5. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 6. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 8. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 9. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players (2018-2024) & (US$ Million)
Table 10. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Players (2018-2024)
Table 11. Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-Related Macular Degeneration (AMD) Therapeutics as of 2022)
Table 12. Ranking of Global Top Age-Related Macular Degeneration (AMD) Therapeutics Companies by Revenue (US$ Million) in 2022
Table 13. Global 5 Largest Players Market Share by Age-Related Macular Degeneration (AMD) Therapeutics Revenue (CR5 and HHI) & (2018-2024)
Table 14. Global Key Players of Age-Related Macular Degeneration (AMD) Therapeutics, Headquarters and Area Served
Table 15. Global Key Players of Age-Related Macular Degeneration (AMD) Therapeutics, Product and Application
Table 16. Global Key Players of Age-Related Macular Degeneration (AMD) Therapeutics, Date of Enter into This Industry
Table 17. Mergers & Acquisitions, Expansion Plans
Table 18. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2018-2024) & (US$ Million)
Table 19. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2018-2024)
Table 20. Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 21. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2024-2034)
Table 22. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2018-2024) & (US$ Million)
Table 23. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2018-2024)
Table 24. Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2024-2034)
Table 26. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 27. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 28. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 29. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 30. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 31. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 32. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 33. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 34. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 35. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 36. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 37. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 38. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 39. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 40. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 41. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 42. Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 43. Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 44. Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 45. Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 46. Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 47. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 48. Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Region (2018-2024) & (US$ Million)
Table 49. Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Region (2024-2034) & (US$ Million)
Table 50. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 51. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 52. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 53. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 54. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 55. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 56. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 57. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 58. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 59. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 60. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 61. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 62. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 64. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 65. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 66. Amgen Inc. Company Details
Table 67. Amgen Inc. Business Overview
Table 68. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
Table 69. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024) & (US$ Million)
Table 70. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics SWOT Analysis
Table 71. Amgen Inc. Recent Development
Table 72. Bausch Health Companies, Inc. Company Details
Table 73. Bausch Health Companies, Inc. Business Overview
Table 74. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
Table 75. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024) & (US$ Million)
Table 76. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics SWOT Analysis
Table 77. Bausch Health Companies, Inc. Recent Development
Table 78. F. Hoffmann-La Roche Ltd. Company Details
Table 79. F. Hoffmann-La Roche Ltd. Business Overview
Table 80. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
Table 81. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024) & (US$ Million)
Table 82. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics SWOT Analysis
Table 83. F. Hoffmann-La Roche Ltd. Recent Development
Table 84. Novartis AG Company Details
Table 85. Novartis AG Business Overview
Table 86. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
Table 87. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024) & (US$ Million)
Table 88. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics SWOT Analysis
Table 89. Novartis AG Recent Development
Table 90. Regeneron Pharmaceuticals Inc. Company Details
Table 91. Regeneron Pharmaceuticals Inc. Business Overview
Table 92. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
Table 93. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024) & (US$ Million)
Table 94. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics SWOT Analysis
Table 95. Regeneron Pharmaceuticals Inc. Recent Development
Table 96. Age-Related Macular Degeneration (AMD) Therapeutics Market Trends
Table 97. Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
Table 98. Age-Related Macular Degeneration (AMD) Therapeutics Market Challenges
Table 99. Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Age-Related Macular Degeneration (AMD) Therapeutics Product Picture
Figure 2. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type: 2022 VS 2034
Figure 4. Wet AMD Features
Figure 5. Dry AMD Features
Figure 6. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 7. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application: 2022 VS 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Research Institute
Figure 11. Other
Figure 12. Age-Related Macular Degeneration (AMD) Therapeutics Report Years Considered
Figure 13. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2018-2034 (US$ Million)
Figure 15. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Region: 2022 VS 2034
Figure 16. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Region in 2018 VS 2022
Figure 17. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share Forecast by Region (2024-2034)
Figure 18. Global Top 10 Age-Related Macular Degeneration (AMD) Therapeutics Countries Ranking by Market Size (US$ Million) in 2022
Figure 19. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 20. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Players in 2022
Figure 21. Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-Related Macular Degeneration (AMD) Therapeutics as of 2022)
Figure 22. The Top 10 and 5 Players Market Share by Age-Related Macular Degeneration (AMD) Therapeutics Revenue in 2022
Figure 23. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Company in 2022
Figure 24. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 25. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 26. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Country (2018-2034)
Figure 27. U.S. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 28. Canada Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 29. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Company in 2022
Figure 30. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 31. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 32. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Country (2018-2034)
Figure 33. Germany Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 34. France Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 35. U.K. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 36. Italy Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 37. Russia Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 38. Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Company in 2022
Figure 39. Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 40. Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 41. Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Region (2018-2034)
Figure 42. China Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 43. Japan Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 44. South Korea Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 45. India Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 46. Australia Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 47. Taiwan Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 48. Indonesia Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 49. Thailand Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 50. Malaysia Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 51. Philippines Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 52. Vietnam Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 53. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Company in 2022
Figure 54. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 55. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 56. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Country (2018-2034)
Figure 57. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 58. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 59. Argentina Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 60. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Company in 2022
Figure 61. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 62. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 63. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Country (2018-2034)
Figure 64. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 65. Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 66. U.A.E Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 67. Amgen Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024)
Figure 68. Bausch Health Companies, Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024)
Figure 69. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024)
Figure 70. Novartis AG Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024)
Figure 71. Regeneron Pharmaceuticals Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2018-2024)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed